←Back to Expert Scholars
Translational Medicine / 转化医学AML Novel Targets, IDH and FLT3
Courtney DiNardo
MD, MSCE
🏢MD Anderson Cancer Center🌐USA
Professor of Leukemia
75
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Courtney DiNardo leads AML trials at MD Anderson and was principal investigator of pivotal IDH and venetoclax trials including VIALE-A. She has defined IDH1/2 inhibitor and venetoclax-based standards in AML. Her work has transformed AML therapy for older and unfit patients.
Share:
🧪Research Fields 研究领域
IDH inhibitors
ivosidenib
enasidenib
venetoclax AML
FLT3 inhibitors
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Courtney DiNardo 的研究动态
Follow Courtney DiNardo's research updates
留下邮箱，当我们发布与 Courtney DiNardo（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment